Clinical Trial Update: Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing two daily doses of rimonabant (5 mg and 20 mg) to placebo for smoking cessation has completed. The STRATUS US study evaluated efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Smoking Cessation | Phase 3 | Status: COMPLETED